Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma.

@article{Nishikawa2013RelationBA,
  title={Relation between antibody to hepatitis B core antigen and survival after curative therapy for non-B non-C hepatocellular carcinoma.},
  author={Hiroki Nishikawa and Yukio Osaki and Akira Arimoto and Ryuichi Kita and Tōru Kimura},
  journal={Anticancer research},
  year={2013},
  volume={33 5},
  pages={2211-9}
}
BACKGROUND/AIM We aimed to examine the relationship between antibodies to hepatitis B core antigen (anti-HBc) positivity and survival in patients with non-B non-C hepatocellular carcinoma (NBNC-HCC) who underwent curative treatment. PATIENTS AND METHODS A total of 260 patients with NBNC-HCC who underwent curative therapy were analyzed. They included 124 anti-HBc-positive patients (47.7%) and 136 anti-HBc-negative patients (52.3%). Overall survival (OS) and recurrence-free survival (RFS) rates… CONTINUE READING